Basal Cell Carcinoma Pipeline Outlook Report 2024
DelveInsight’s, “Basal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 25+ Basal Cell Carcinoma companies and 25+ pipeline drugs in the Basal Cell Carcinoma pipeline landscape. It covers the Basal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Basal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Basal Cell Carcinoma Pipeline Report
- DelveInsight’s Basal Cell Carcinoma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma treatment.
- The leading companies working in the Basal Cell Carcinoma market include PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
- Promising Basal Cell Carcinoma Pipeline Therapies in the various stages of development include BF-200 ALA, Methyl-aminolevulinate, Cemiplimab, STP705, Patidegib, LDE225, Imiquimod, Vismodegib, and others.
- December 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for vidutolimod and cemiplimab. The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
- December 2023: Replimune Inc. announced a study of Phase 1 & 2 clinical trials for RP1, intra-tumoral injection, oncolytic virus. This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.
- On June 2023, Regeneron Pharmaceuticals announced a study of Phase 1 Clinical Trials for Cemiplimab. The primary objective is to characterize the safety and tolerability of cemiplimab injected intralesionally in patients with Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC).
- On March 2023, Sirnaomics announced a study of Phase 2 Clinical Trials for This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
Request a sample and discover the recent advances in Basal Cell Carcinoma Treatment Drugs @ Basal Cell Carcinoma Pipeline Outlook Report
The Basal Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Basal Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Basal Cell Carcinoma clinical trial landscape.
Basal Cell Carcinoma Overview
Basal Cell Carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma.
Find out more about Basal Cell Carcinoma Treatment Landscape @ Drugs for Basal Cell Carcinoma Treatment
Basal Cell Carcinoma Emerging Drugs Profile
- Patidegib: PellePharm
- AIV001: AiViva BioPharma
Basal Cell Carcinoma Pipeline Therapeutics Assessment
The Basal Cell Carcinoma pipeline report proffers an integral view of the Basal Cell Carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Basal Cell Carcinoma Pipeline Therapies @ Basal Cell Carcinoma Clinical Trials Assessment
Scope of the Basal Cell Carcinoma Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
- Basal Cell Carcinoma Pipeline Therapies- BF-200 ALA, Methyl-aminolevulinate, Cemiplimab, STP705, Patidegib, LDE225, Imiquimod, Vismodegib, and others.
Dive deep into rich insights for new drugs for Basal Cell Carcinoma Treatment, Visit @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Basal Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Basal Cell Carcinoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Patidegib: PellePharm
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IO103: IO Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- AIV001: AiViva BioPharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Cannabidiol: Leaf Vertical
- Drug profiles in the detailed report…..
- Inactive Products
- Basal Cell Carcinoma Key Companies
- Basal Cell Carcinoma Key Products
- Basal Cell Carcinoma- Unmet Needs
- Basal Cell Carcinoma- Market Drivers and Barriers
- Basal Cell Carcinoma- Future Perspectives and Conclusion
- Basal Cell Carcinoma Analyst Views
- Appendix
For further information on the Basal Cell Carcinoma Pipeline therapeutics, reach out to Basal Cell Carcinoma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
